Treatment of Coccidioidomycosis

Graybill, John R.

doi:10.1111/j.1749-6632.1988.tb40445.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Immitis1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1990

2006

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the potential severity of coccidioidomycosis in transplant patients and other immunosuppressed patients, therapy is always indicated [2,3,5,6,8,9,26,27]. Amphotericin B is still the agent most frequently used as initial therapy for coccidioidomycosis in immunosuppressed patients who have disseminated infection or are clinically unstable [2,3,5,6,8,9,[18][19][20]27].…”

Section: Immitismentioning

confidence: 99%

Coccidioidomycosis in Liver Transplant Patients

Holt¹,

Winston²,

Kubak³

et al. 1997

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Immitismentioning

confidence: 99%

Coccidioidomycosis in Liver Transplant Patients

Holt¹,

Winston²,

Kubak³

et al. 1997

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations

Tucker

Denning

Arathoon

et al. 1990

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Coccidioidomycosis

Anstead

Graybill

2006

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

The difficulties in managing this potentially horrific disease, with its myriad manifestations, are immense, because host factors dramatically impact outcome. Coccidioidomycosis should warrant great respect among clinicians, because, even with dramatic improvements in therapies, outcomes remain poor. Although there have been outstanding successes with these new therapies, tragic losses after years of immense patient suffering still occur. Coccidioidomycosis is a geographically restricted fungus but is one that inflicts tremendous suffering on affected patients. In addition, because of travel and the influx of susceptible hosts, dramatic increases in patients at risk for infection are seen throughout the southwest United States. The extended-spectrum azoles, such as posaconazole and voriconazole, may prove to be more efficacious in the treatment of coccidioidomycosis than prior agents, including amphotericin B, fluconazole, and itraconazole. Additional resources are needed to conduct randomised, controlled clinical trials for the treatment of this disease.

show abstract

Treatment of Coccidioidomycosis

Cited by 5 publications

References 26 publications

Coccidioidomycosis in Liver Transplant Patients

Coccidioidomycosis in Liver Transplant Patients

Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations

Coccidioidomycosis

Contact Info

Product

Resources

About